Seroreactivity of antibodies to hepatitis B core antigen among hepatitis B surface antigen‐screened negative blood donors and its implications for blood safety in a resource‐constrained country
Vox Sanguinis · 2024
DOI: 10.1111/vox.13576 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vox Sanguinis, 2024. Verfasst von Rhoda T Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Tropical Medicine, Muntinlupa City, Philippines. Hauptthemen laut MEDLINE: Hepatitis B Core Antigens, Hepatitis B. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Abbott Laboratories.
Abstract (Originalsprache)
Background and Objectives Transfusion‐related hepatitis B infections have been reduced significantly with the implementation of blood screening using both serology and nucleic acid amplification technology (NAT) in developed countries. However, in resource‐constrained countries, where NAT is inaccessible, the risk persists from early acute and occult cases. This study aimed to determine the antibodies to hepatitis B core antigen (anti‐HBc) reactive rate among hepatitis B surface antigen (HBsAg)‐screened negative blood donors and its impact on blood safety in the Philippines. Materials and Methods A total of 1602 HBsAg‐negative samples, randomly collected from nine leading blood service facilities representative of each region in the Philippines, were tested for anti‐HBc immunoglobulin M (IgM), Total and antibodies to HBsAg (anti‐HBs) using the Architect i2000SR Immunoassay Analyser (Abbott Laboratories, IL). Anti‐HBc IgM and/or Total repeat reactive were further tested for hepatitis B virus (HBV) NAT using the Cobas TaqScreen MPX v2.0 (Roche Diagnostics, Basel).
Results
Overall, 19.16% HBsAg‐negative samples ( n = 307/1602) were reactive for either anti‐HBc IgM or Total or a combination of both, of which 1.3% ( n = 4/307) had detectable HBV‐DNA and 80.5% ( n = 247/307) were anti‐HBs positive. About the anti‐HBs titres, 30.27% ( n = 485/1602) were positive (≥10 IU/L) with 55.67% ( n = 270/485) having titres ≥100 IU/L. Anti‐HBs‐only‐positive samples were 14.85% ( n = 238/1602).
Conclusion
We observed a high anti‐HBc reactive rate (19.16%) with 3.7% anti‐HBc‐only reactive (anti‐HBs negative) and 1.3% HBV‐DNA positive. This warrants the need to reconsider existing screening practices to improve blood safety in the country.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute for Tropical Medicine, Muntinlupa City, Philippines.
- Abbott Laboratories Singapore Pte Ltd., Singapore.
- National Council for Blood Services, Department of Health, Manila, Philippines.
ORCID-Profile: Sonu Bhatnagar
Förderung
- Abbott Laboratories
Zitieren
APA
Yu, R. T., Punzalan, K. A. P., Bhatnagar, S., Lutero, R. B., Chamen, I. M. S., Masangkay, C. B., & Arcellana-Nuqui, E. Y. (2024). Seroreactivity of antibodies to hepatitis B core antigen among hepatitis B surface antigen‐screened negative blood donors and its implications for blood safety in a resource‐constrained country. Vox Sanguinis. https://doi.org/10.1111/vox.13576
Vancouver
Yu RT, Punzalan KAP, Bhatnagar S, Lutero RB, Chamen IMS, Masangkay CB, et al. Seroreactivity of antibodies to hepatitis B core antigen among hepatitis B surface antigen‐screened negative blood donors and its implications for blood safety in a resource‐constrained country. Vox Sanguinis. 2024. doi:10.1111/vox.13576
BibTeX
@article{Yu2024,
author = {Yu, Rhoda T and Punzalan, Kenneth Aristotle P and Bhatnagar, Sonu and Lutero, Raymond B and Chamen, Iza Mae S and Masangkay, Catherine B and Arcellana-Nuqui, Elizabeth Y},
title = {Seroreactivity of antibodies to hepatitis B core antigen among hepatitis B surface antigen‐screened negative blood donors and its implications for blood safety in a resource‐constrained country},
journal = {Vox Sanguinis},
year = {2024},
doi = {10.1111/vox.13576}
}
EUVIMED